Literature DB >> 9453064

Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities.

D Boschi1, A Di Stilo, C Cena, M Lolli, R Fruttero, A Gasco.   

Abstract

PURPOSE: A series of derivatives having a propranolol-like moiety linked to NO-donor furoxan substructures were synthesized. The main objective of this investigation was to obtain agents with mixed NO-dependent vasodilating and beta-blocking activities.
METHODS: Most of the target compounds were synthesized from the appropriate furoxans bearing XCH2CH2NH2 (X = O, S, SO2) chains at the 4 position of the ring, using Al(C2H5)3 in methylene chloride solution and (+/-)2,3-epoxypropyl 1-naphtyl ether. Two of the final products (X = CONH) were obtained by coupling the appropriate furoxancarboxylic acids with N-[2-hydroxy-3-(1-naphthoxy)propyl]-ethylenediamine. beta 1- and beta 2-blocking activities were examined on isolated guinea pig right atria and on guinea pig trachea respectively. Vasodilating properties were assessed on endothelium denuded strips of rat aorta.
RESULTS: Some derivatives behave as well balanced "hybrids" displaying NO-dependent vasodilating and beta-blocking properties in the same concentration range. Some others display either prevalent beta-blocking or vasodilating activity. Generally speaking hybrid formation lowers the affinity for beta-receptors, in particular for beta 2-type, to give an increase in beta 1/beta 2 selectivity.
CONCLUSIONS: The furoxan system is a flexible tool in designing analogues of propranolol whose NO-donating and beta-blocking properties are modulated over a wide range.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453064     DOI: 10.1023/a:1012136030849

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Water soluble furoxan derivatives as NO prodrugs.

Authors:  G Sorba; C Medana; R Fruttero; C Cena; A Di Stilo; U Galli; A Gasco
Journal:  J Med Chem       Date:  1997-02-14       Impact factor: 7.446

Review 2.  No-donors: an emerging class of compounds in medicinal chemistry.

Authors:  A Gasco; R Fruttero; G Sorba
Journal:  Farmaco       Date:  1996-10

Review 3.  Nitric oxide: a new paradigm for second messengers.

Authors:  J F Kerwin; J R Lancaster; P L Feldman
Journal:  J Med Chem       Date:  1995-10-27       Impact factor: 7.446

4.  Characterization of furoxans as a new class of tolerance-resistant nitrovasodilators.

Authors:  M Hecker; W Vorhoff; A T Bara; P I Mordvintcev; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

5.  Simulation of the diffusion and reaction of endogenously produced nitric oxide.

Authors:  J R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor.

Authors:  H Bohn; J Brendel; P A Martorana; K Schönafinger
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans.

Authors:  M Feelisch; K Schönafinger; E Noack
Journal:  Biochem Pharmacol       Date:  1992-09-25       Impact factor: 5.858

8.  Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation.

Authors:  C Medana; G Ermondi; R Fruttero; A Di Stilo; C Ferretti; A Gasco
Journal:  J Med Chem       Date:  1994-12-09       Impact factor: 7.446

9.  The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities.

Authors:  R Fruttero; D Boschi; A Di Stilo; A Gasco
Journal:  J Med Chem       Date:  1995-12-08       Impact factor: 7.446

10.  A new class of furoxan derivatives as NO donors: mechanism of action and biological activity.

Authors:  R Ferioli; G C Folco; C Ferretti; A M Gasco; C Medana; R Fruttero; M Civelli; A Gasco
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

View more
  4 in total

1.  Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.

Authors:  Isaac T Schiefer; Lawren VandeVrede; Mauro Fa'; Ottavio Arancio; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2012-03-30       Impact factor: 7.446

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

3.  Studies on agents with mixed NO-dependent and calcium channel antagonistic vasodilating activities.

Authors:  C Cena; S Visentin; A Di Stilo; D Boschi; R Fruttero; A Gasco
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

4.  New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Authors:  Stefano Guglielmo; Daniela Cortese; Francesca Vottero; Barbara Rolando; Valerie P Kommer; David L Williams; Roberta Fruttero; Alberto Gasco
Journal:  Eur J Med Chem       Date:  2014-07-03       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.